Analysts Offer Predictions for Myriad Genetics Q2 Earnings

Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2026 earnings estimates for shares of Myriad Genetics in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings of ($0.02) per share for the quarter. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Myriad Genetics' current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics' Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at $0.02 EPS.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.12). The company had revenue of $210.60 million for the quarter, compared to the consensus estimate of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period in the prior year, the business earned ($0.12) earnings per share.

Several other analysts have also recently commented on MYGN. Piper Sandler decreased their target price on Myriad Genetics from $24.00 to $14.00 and set a "neutral" rating for the company in a research report on Thursday, January 30th. UBS Group lowered their target price on Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 25th. Morgan Stanley dropped their target price on Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating on the stock in a report on Monday, November 18th. Craig Hallum assumed coverage on shares of Myriad Genetics in a report on Wednesday, February 12th. They set a "buy" rating and a $29.00 price target for the company. Finally, Bank of America dropped their price objective on shares of Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating on the stock in a research note on Monday. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $22.00.

Remove Ads

Myriad Genetics Trading Down 3.2 %

Shares of NASDAQ:MYGN traded down $0.34 during mid-day trading on Thursday, hitting $10.39. The stock had a trading volume of 1,025,092 shares, compared to its average volume of 1,176,091. Myriad Genetics has a 12-month low of $9.76 and a 12-month high of $29.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The company has a market cap of $945.85 million, a PE ratio of -7.99 and a beta of 1.88. The company's 50 day moving average is $13.28 and its 200-day moving average is $18.91.

Hedge Funds Weigh In On Myriad Genetics

Institutional investors have recently modified their holdings of the company. Creative Planning boosted its holdings in Myriad Genetics by 9.8% during the third quarter. Creative Planning now owns 9,949 shares of the company's stock valued at $273,000 after acquiring an additional 892 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Myriad Genetics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company's stock valued at $87,000 after buying an additional 583 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Myriad Genetics by 182.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 11,417 shares of the company's stock worth $313,000 after buying an additional 7,381 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Myriad Genetics by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,468 shares of the company's stock worth $478,000 after buying an additional 6,834 shares during the period. Finally, New York State Teachers Retirement System lifted its holdings in shares of Myriad Genetics by 4.4% during the third quarter. New York State Teachers Retirement System now owns 73,900 shares of the company's stock worth $2,024,000 after buying an additional 3,102 shares during the last quarter. Institutional investors own 99.02% of the company's stock.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.